2016 Fiscal Year Final Research Report
Development of Epstein-Barr virus (EBV) specific cytotoxic T lymphocytes (CTL) therapy for EBV-LPD after hematopoietic stem cell transplantation
| Project/Area Number |
26461580
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KIMURA Hiroshi 名古屋大学, 大学院医学系研究科, 教授 (30303621)
MIZUNO Masaaki 名古屋大学, 医学部附属病院, 病院教授 (70283439)
|
|---|
| Research Collaborator |
LEEN Ann 米国ベイラー医科大学, Pediatrics-Hem-Onc Cell & Gene, 助教
SAJI Hiroo HLA研究所, 所長
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | ＥＢウイルス / 造血幹細胞移植 / ＣＴＬ |
|---|
| Outline of Final Research Achievements |
We analyzed the relation of EBV reactivation and Anti-thymocyte globulin (ATG) blood concentration in 90 cases and revealed that EBV reactivation was significantly more in high ATG concentration group. We could successfully developed EBV specific CTLs from 3rd party donors using not only HLA A2402/A0201 peptides but also HLA-A11 restricted peptides. We started the phase 1 clinical trial of EBV specific CTL therapy from the 3rd party donors.
|
| Free Research Field |
血液学
|
